Reductionism and proxy failure: From neuroscience to target-based drug discovery

被引：0

作者：

Sadri, Arash ^{[1
,2
]}

Paknezhad, Sepideh ^{[3
]}

机构：

[1] Lyceum Sci Char, Tehran, Iran

[2] Univ Tehran Med Sci, Students Sci Res Ctr, Interdisciplinary Neurosci Res Program INRP, Tehran, Iran

[3] Islamic Azad Univ, Dept Psychol, Sari Branch, Sari, Iran

来源：

BEHAVIORAL AND BRAIN SCIENCES | 2024年 / 47卷

关键词：

D O I：

10.1017/S0140525X23002893

中图分类号：

B84 [心理学];

学科分类号：

04 ; 0402 ;

摘要：

Reductionist methodologies reduce phenomena to some of their lower-level components. Researchers gradually shift their focus away from observing the actual object of study toward investigating and optimizing such lower-level proxies. Following reductionism, these proxies progressively diverge further from the original object of study. We vividly illustrate this in the evolution of target-based drug discovery from rational and phenotypic drug discovery.

引用

页数：56

共 50 条

[41] Target-Based Drug Discovery: the Emerging Success of Frontal Affinity Chromatography Coupled to Mass Spectrometry
Calleri, Enrica
Temporini, Caterina
Caccialanza, Gabriele
Massolini, Gabriella
CHEMMEDCHEM, 2009, 4 (06) : 905 - 916
[42] In Silico Predictions of hERG Channel Blockers in Drug Discovery: From Ligand-Based and Target-Based Approaches to Systems Chemical Biology
Taboureau, Olivier
Jorgensen, Flemming Steen
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2011, 14 (05) : 375 - 387
[43] Bridging the Gap between Target-Based and Cell-Based Drug Discovery with a Graph Generative Multitask Model
Hu, Fan
Wang, Dongqi
Huang, Huazhen
Hu, Yishen
Yin, Peng
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2022, 62 (23) : 6046 - 6056
[44] Comment on: Target-based discovery of a broad-spectrum flukicide
Tripathi, Timir
PLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (11):
[45] Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery
P. Chellapandi
S. Saranya
Medicinal Chemistry Research, 2020, 29 : 1777 - 1791
[46] From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity
Durieu, Emilie
Prina, Eric
Leclercq, Olivier
Oumata, Nassima
Gaboriaud-Kolar, Nicolas
Vougogiannopoulou, Konstantina
Aulner, Nathalie
Defontaine, Audrey
No, Joo Hwan
Ruchaud, Sandrine
Skaltsounis, Alexios-Leandros
Galons, Herve
Spaeth, Gerald F.
Meijer, Laurent
Rachidi, Najma
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 2822 - 2833
[47] A target-based discovery from a parasitic helminth as a novel therapeutic approach for autoimmune diseases
Ni, Yangyue
Xiong, Ruiyan
Zhu, Yuxiao
Luan, Ning
Yu, Chuanxin
Yang, Kun
Wang, Huiquan
Xu, Xuejun
Yang, Yuxuan
Sun, Siyu
Shi, Liyun
Padde, Jon Rob
Chen, Lin
Chen, Lu
Hou, Min
Xu, Zhipeng
Lai, Ren
Ji, Minjun
EBIOMEDICINE, 2023, 95
[48] A Knowledge-Guided Graph Learning Approach Bridging Phenotype- and Target-Based Drug Discovery
Ye, Qing
Zeng, Yundian
Jiang, Linlong
Kang, Yu
Pan, Peichen
Chen, Jiming
Deng, Yafeng
Zhao, Haitao
He, Shibo
Hou, Tingjun
Hsieh, Chang-Yu
ADVANCED SCIENCE, 2025,
[49] Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery
Chellapandi, P.
Saranya, S.
MEDICINAL CHEMISTRY RESEARCH, 2020, 29 (10) : 1777 - 1791
[50] Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies
Moshawih, Said
Lim, Ai Fern
Ardianto, Chrismawan
Goh, Khang Wen
Kifli, Nurolaini
Goh, Hui Poh
Jarrar, Qais
Ming, Long Chiau
BIOMOLECULES, 2022, 12 (07)

← 1 2 3 4 5 →